Comparison of 10-year overall survival between patients with G1 and G2 grade Ta bladder tumors

被引:13
|
作者
Balan, Daniel [1 ,2 ,3 ]
Martha, Orsolya [2 ]
Chibelean, Calin Bogdan [2 ]
Tataru, Sabin [2 ]
Voidezan, Septimiu [4 ]
Sin, Anca [1 ]
Matei, Victor Deliu [5 ]
Vartolomei, Mihai Dorin [1 ,2 ,5 ,6 ]
Lucarelli, Giuseppe [7 ]
Cioffi, Antonio [5 ]
Del Giudice, Francesco [8 ]
De Berardinis, Ettore [8 ]
Borda, Angela [9 ]
Busetto, Gian Maria [8 ]
Ferro, Matteo [5 ]
Pytel, Akos [3 ]
Porav-Hodade, Daniel [2 ]
机构
[1] Univ Med & Pharm, Dept Cell & Mol Biol, Targu Mures, Romania
[2] Univ Med & Pharm, Dept Urol, Targu Mures, Romania
[3] Univ Pecs, Dept Urol, Pecs, Hungary
[4] Univ Med & Pharm, Dept Epidemiol, Targu Mures, Romania
[5] European Inst Oncol, Div Urol, Via Ripamonti 435, I-20141 Milan, Italy
[6] Med Univ Vienna, Dept Urol, Vienna, Austria
[7] Univ Bari, Dept Emergency & Organ Transplantat, Urol Androl & Kidney Transplantat Unit, Bari, Italy
[8] Sapienza Univ Rome, Dept Urol, Rome, Italy
[9] Univ Med & Pharm, Dept Histol, Targu Mures, Romania
关键词
G1 and G2 grade nonmuscle invasive bladder cancer; long-term; overall survival; progression; recurrence; BACILLUS-CALMETTE-GUERIN; FOLLOW-UP; UROTHELIAL CARCINOMA; ONCOLOGICAL OUTCOMES; CANCER; PROGRESSION; THERAPY; T1; RECURRENCE; GUIDELINES;
D O I
10.1097/MD.0000000000010522
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To compare long-term overall survival (OS) in patients with G1 and G2 grade Ta bladder cancer after transurethral resection of bladder tumors (TURBTs). Secondary aim was to investigate clinical and pathologic prognostic factors for OS of Ta patients, except G3/high grade (HG). A total of 243 patients, retrospectively selected, with Ta nonmuscle invasive bladder cancer (NMIBC) underwent TURBT between January 2006 and December 2008 (median follow-up 109 months). Inclusion criteria were: Ta at first manifestation, G1 or G2 grade with no associated carcinoma in situ (CIS). Seventy-nine patients were excluded due to concomitant CIS (1), G3/HG tumors (47), and lost to follow-up (31). Ethical approval was obtained from the Ethical Committee of the Mures County Hospital. Statistical analysis was performed using STATA 11.0. Following inclusion criteria, 164 patients with primary G1 or G2 Ta tumors, were enrolled. Recurrence was observed in 26 (15.8%) and progression in 5 (3%) patients. Ten-year survival in G1 patients was 67.8% (CI 54.3-78.1) and in G2 patients 59% (CI 49-67.3) (P=.31). Univariable and multivariable logistic regression analysis underlined that advanced age at diagnosis (hazard ratio [HR] 1.10) and no Bacillus Calmette-Guerin (BCG) treatment (HR 0.24 and 0.29) were independent predictors for death at 10 years after diagnosis. Long-term analysis confirms that patients with well differentiated (G1) and moderately well differentiated (G2) Ta tumors have similar OS. A longer OS was even reported in those who underwent BCG adjuvant therapy.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] FOLFOX in pancreatic G1 and G2 neuroendocrine tumors
    Bengueddache, A.
    Kehili, H.
    Tidjane, A.
    Remini, A.
    Boudjnane, N.
    Tabeti, B.
    Tilioua, O.
    Bereksi-Reguig, F.
    Zaoui, C.
    JOURNAL OF NEUROENDOCRINOLOGY, 2023, 35 : 215 - 215
  • [2] Watchful waiting policy in recurrent Ta G1 bladder tumors
    Gofrit, ON
    Pode, D
    Lazar, A
    Katz, R
    Shapiro, A
    EUROPEAN UROLOGY, 2006, 49 (02) : 303 - 307
  • [3] Stratifying risk for multiple, recurrent, and large (≥3 cm) Ta, G1/G2 tumors in non-muscle-invasive bladder cancer
    Suh, Jungyo
    Jung, Jae Hyun
    Kwak, Cheol
    Kim, Hyeon Hoe
    Ku, Ja Hyeon
    INVESTIGATIVE AND CLINICAL UROLOGY, 2021, 62 (04) : 408 - 415
  • [4] Surgical Treatment of Small Intestinal Neuroendocrine Tumors G1/G2
    Selberherr, Andreas
    Niederle, Martin B.
    Niederle, Bruno
    VISCERAL MEDICINE, 2017, 33 (05) : 340 - 343
  • [5] Differences in the microRNA expression of G1 and G2 pancreatic neuroendocrine tumors
    Nyiro, G.
    Szeredas, B.
    Vekony, B.
    Borka, K.
    Zalatnai, A.
    Dezso, K.
    Kovalszky, I
    Igaz, P.
    JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 36 - 36
  • [6] miRNA Expression Profiling in G1 and G2 Pancreatic Neuroendocrine Tumors
    Nyiro, Gabor
    Szeredas, Balint Kende
    Decmann, Abel
    Herold, Zoltan
    Vekony, Balint
    Borka, Katalin
    Dezso, Katalin
    Zalatnai, Attila
    Kovalszky, Ilona
    Igaz, Peter
    CANCERS, 2024, 16 (14)
  • [7] Can Ampullary G1 and G2 Neuroendocrine Tumors Be Cured by Endoscopic Papillectomy?
    Zhang, Wengang
    Chai, Ningli
    Linghu, Enqiang
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (06)
  • [8] Differences between Grades G1 and G2 Hypovascular Pancreatic Neuroendocrine Tumors and Pancreatic Neuroendocrine Carcinoma
    Chen, Xiao
    Wang, Zhongqiu
    RADIOLOGY, 2017, 285 (01) : 331 - 332
  • [9] CLEAVAGE OF CARTILAGE PROTEOGLYCAN BETWEEN G1 AND G2 DOMAINS BY STROMELYSINS
    FOSANG, AJ
    NEAME, PJ
    HARDINGHAM, TE
    MURPHY, G
    HAMILTON, JA
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1991, 266 (24) : 15579 - 15582
  • [10] Comparative Analysis of CT Features in pNENs with Different Pathological Grade (G1 and G2)
    Tang, J.
    Shao, C.
    Shao, C.
    Yang, G.
    Ji, M.
    NEUROENDOCRINOLOGY, 2017, 105 : 56 - 56